You have accessJournal of UrologyDiscussed Poster, Sunday, May 21, 2006, 1:00 - 4:00 pm1 Apr 2006344: Assessment of Pelvic Neuropathy in Female Stress Urinary Incontinence Germar M. Pinggera, Robert Spranger, Hannes Strasser, Peter Rehder, and Georg Bartsch Germar M. PinggeraGermar M. Pinggera More articles by this author , Robert SprangerRobert Spranger More articles by this author , Hannes StrasserHannes Strasser More articles by this author , Peter RehderPeter Rehder More articles by this author , and Georg BartschGeorg Bartsch More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(18)32600-4AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail "344: Assessment of Pelvic Neuropathy in Female Stress Urinary Incontinence." The Journal of Urology, 175(4S), p. 113 © 2016 by American Urological AssociationFiguresReferencesRelatedDetails Volume 175Issue 4SApril 2006Page: 113 Advertisement Copyright & Permissions© 2016 by American Urological AssociationMetricsAuthor Information Germar M. Pinggera More articles by this author Robert Spranger More articles by this author Hannes Strasser More articles by this author Peter Rehder More articles by this author Georg Bartsch More articles by this author Expand All Advertisement PDF downloadLoading ...

BACKGROUND. To determine longitudinal PSA changes over a period of Ill years in patient with and without prostate cancer.METHODS. Serial PSA measurements performed over 10 years were evaluated in 353 men who eventually developed prostate cancer and in 2.462 participants of a screening program without prostatic malignancy.RESULTS. In men with cancer, mean tPSA increased from 2.28 ng/ml at 10 years before diagnosis to 6.37 ng/ml at the time of postive biopsy (PSA velocity; 0.409 ng/ml/year). PSA velocity was significantly associated with Gleason scores and pathologic stage. In the benign group (n = 2.462), mean tPSA increased from 1.18 to 1.49 ng/ml over a period of 10 years (PSA velocity of 0.03 ng/ml/year). Of the subjects with tPSA levels of 2 ng/ml or less, 2 years prior to cancer diagnosis, 11.4% had tPSA values of more than 4 ng/ml at the time of biopsy. Of the 972 men with tPSA below 1 ng/ml 2 years before the most recent measurement was obtained, 966 (99.4%) had no evidence of prostate cancer 2 years later, while six were found to have malignancies (0.6%.).CONCLUSIONS. Longitudinal PSA changes in men with and without prostate cancer are significantly different. Annual testing may not be required in men with baseline tPSA levels of 1 ng/ml or below, whereas in patients with levels higher than 1 ng/ml, it seems to be indicated because of the significant percentage of men presenting with tPSA levels of more than 4 ng/ ml two years later. (c) 2005 Wiley-Liss, Inc.

PURPOSE:Transurethral resection of the prostate (TURP) is still the gold standard for the surgical treatment of symptomatic benign prostatic hyperplasia. However, the associated morbidity and blood loss remain concerns. A coagulating intermittent cutting (CIC) device with constant voltage pulses and controlled pulse intervals was recently developed. The impact of CIC on bleeding and blood transfusion rates as well as the occurrence of the TUR syndrome were investigated.MATERIALS AND METHODS:From January 2000 to July 2002, 271 consecutive patients with symptomatic benign prostatic hyperplasia underwent TURP with the CIC device. In addition to blood transfusion rates, serum hemoglobin and electrolytes were determined in all patients immediately before and after TURP.RESULTS:The mortality rate in the 271 patients subjected to TURP was 0.0%. Mean decrease in hemoglobin after TURP was 1.08 mg/dl. Intraoperative and postoperative blood transfusions were required in 7 patients (2.6%), and clinical signs of the transurethral resection syndrome were noted in 1.1% of patients.CONCLUSIONS:Coagulating intermittent cutting dramatically improves the safety of TURP by decreasing intraoperative and postoperative blood loss, and the rate of blood transfusions. With this blood sparing device we anticipate a lower incidence of hemostatic complications from TURP.

Objectives. To evaluate the effect of periprostatic infiltration with local anesthesia on the level of discomfort associated with transrectal ultrasound-guided needle biopsy of the prostate. Transrectal ultrasound-guided needle biopsy of the prostate is the standard procedure to diagnose prostate cancer.Methods. A prospective, randomized, double-blind study was performed on 100 men referred for biopsy of the prostate. Fifty subjects were randomized to periprostatic injection of 10 mL of 2% lidocaine solution without epinephrine, and 50 were randomized to injection of placebo (10 mL of 0.9% NaCl). Each subject completed three 10-point visual analog scales for pain after a series of 15 needle biopsies. Pain was rated during the biopsy, diagnostic investigation, and injection of lidocaine.Results. Patients who received local anesthesia had significantly lower visual analog scale scores compared with the group without lidocaine during the biopsy (mean score 0.76 versus 3.62, P < 0.001) and diagnostic examination (mean score 1.08 versus 1.86, P = 0.025). Lidocaine injection caused no adverse effects.Conclusions. Periprostatic injection of lidocaine represents a simple and safe procedure that significantly reduces discomfort during probe manipulation and biopsy. We recommend this procedure in men undergoing transrectal ultrasound-guided prostate biopsy. (C) 2003, Elsevier Science Inc.

A high variation rate exists in the venous anatomy of the kidney. Single or multiple veins are common. Rare anomalies have exclusively been described previously on the left side. We report a case of congenitally absent right renal vein, found by coincidence in assessment of right flank pain.

The present study was designed to investigate whether the clinical or pathologic features of prostate cancer (PCa) are related to the number of repeat biopsies required to establish the diagnosis of PCa.

BACKGROUND. The introduction of prostate-specific antigen (PSA) contributed to a shift in tumor stage at diagnosis in patients with prostate cancer. The aim of the present study was to evaluate the effects of PSA screening with low PSA cut-off values on mean total and percent-free PSA levels in patients with prostate cancers at the time of diagnosis as well as on pathologic stage and mean Gleason scores in positive biopsies and radical prostatectomy specimens.METHODS. Data of 875 patients who were diagnosed with prostate cancers between 1996 and 2001 were analyzed. Patients were stratified into six groups according to the year of biopsy. Annual changes in total and percent-free PSA values, in Gleason scores of biopsies and radical prostatectomy specimens, and in pathologic stages of radical prostatectomy specimens were assessed.RESULTS. Mean PSA of patients diagnosed with prostate cancer decreased from 13.11 ng/ml (percent-free PSA: 11.89%) in 1996 to 7.33 ng/ml (percent-free PSA: 12.58%) in 2001 (P < 0.05). The percentage of organ-confined prostatectomy specimens increased from 64.3% in 1996 to 81.5% in 2001 (P < 0.05). However, mean Gleason scores increased from 5.23 to 6.33 over the 6 years (P < 0.05). The percentage of patients with biopsy-proven prostate cancers and PSA values below 4 ng/ml increased from 14.0% in 1996 to 39.2% in 2001. In the group with PSA values below 4 ng/ml organ-confined cancers were found in 80.0-95.2% of patients.CONCLUSIONS. PSA screening with low cut-off levels has led to a significant reduction of mean baseline PSA levels in prostate cancer patients and to a significant increase in the percentage of organ-confined radical prostatectomy specimens, whereas mean Gleason scores have remained relatively constant. (C) 2003 Wiley-Liss, Inc.

Objectives: To evaluate the Targis System(R) in men presenting with acute urinary retention, high prostate volume and high operative risk.Materials and Methods: Between August 1997 and March 200 1, a total of 78 patients in poor general health status presenting with large prostate glands and acute urinary retention secondary to BPH were treated with the Targis TUMT device. Mean age, mean prostate volume, and the percentage of patients who were able to urinate spontaneously after the procedure as well as mean peak and average flow rates and mean residual urine volume were evaluated.Results: 68 (87.1%) of the 78 patients were able to urinate spontaneously three months after the procedure. In 5 (7.3%) of the 68 patients urinary retention recurred within two years. Following treatment, the mean peak flow rate in the 68 successfully treated patients was 11.1 ml/s, while the mean postvoid residual volume was 46 ml.Conclusion: Based on these data we recommend transurethral thermotherapy using the Targis System(R) for patients in poor general health presenting with urinary retention and prostate volumes of more than 35 cc in whom TURP is not possible. (C) 2002 Elsevier Science B.V. All rights reserved.

We present 2 cases of free-floating intravesical tumors that histologically were demonstrated to be of prostatic origin. Although diagnosis could not be made endoscopically, removal of the foreign bodies was performed via an endoscopic approach.

No AccessJournal of UrologyCLINICAL UROLOGY: Case Reports1 Jul 2002Polyorchidism: A Strange Anomaly With Unsuspected Properties Robert Spranger, Marcel Gunst, and Michael Kühn Robert SprangerRobert Spranger , Marcel GunstMarcel Gunst , and Michael KühnMichael Kühn View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)64868-9AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail "Polyorchidism: A Strange Anomaly With Unsuspected Properties." The Journal of Urology, 168(1), p. 198 References 1 : Polyorchidism with normal spermatogenesis and equal sized testes: a theory of embryological development. J Urol1978; 120: 638. Link, Google Scholar 2 : Polyorchidism: a case report and review of the literature. Eur J Pediatr Surg1992; 2: 306. Google Scholar 3 : Neoplasms of the testis. In: Campbell's Urology. Edited by . Philadelphia: W. B. Saunders Co.1998: 2411. Google Scholar From the Departments of Urology, Universitätsklinik Innsbruck, Innsbruck, Austria, Kantonsspital Olten, Olten, Switzerland, and Johanniter-Klinikum Stendal, Stendal, Germany© 2002 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byBergholz R and Wenke K (2018) Polyorchidism: A Meta-AnalysisJournal of Urology, VOL. 182, NO. 5, (2422-2427), Online publication date: 1-Nov-2009. Volume 168Issue 1July 2002Page: 198 Advertisement Copyright & Permissions© 2002 by American Urological Association, Inc.Keywordsurogenital abnormalitiestesticular neoplasmstestisMetricsAuthor Information Robert Spranger More articles by this author Marcel Gunst More articles by this author Michael Kühn More articles by this author Expand All Advertisement PDF downloadLoading ...